APAC

About Aplagon

Aplagon is a Finnish private biotech founded in 2018, advancing APAC, a novel vascular injury-targeting molecule with combined antiplatelet, anticoagulant, and anti-inflammatory properties. The company is currently in Phase 2a clinical trials for Peripheral Arterial Occlusive Disease/Chronic Limb Threatening Ischemia, having secured EUR 7 million in financing in early 2025 to advance this program. Backed by leading Finnish investors and based on pioneering research from the Wihuri Research Institute, Aplagon aims to address the significant unmet need in thrombotic cardiovascular diseases where current therapies are only partially effective.

About Aplagon

Aplagon is a Finnish private biotech founded in 2018, advancing APAC, a novel vascular injury-targeting molecule with combined antiplatelet, anticoagulant, and anti-inflammatory properties. The company is currently in Phase 2a clinical trials for Peripheral Arterial Occlusive Disease/Chronic Limb Threatening Ischemia, having secured EUR 7 million in financing in early 2025 to advance this program. Backed by leading Finnish investors and based on pioneering research from the Wihuri Research Institute, Aplagon aims to address the significant unmet need in thrombotic cardiovascular diseases where current therapies are only partially effective.

Therapeutic Areas